Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

FOLLOW US: 

September 19, 2019

Fournier’s Gangrene Risk from Invokana Potentially Confirmed by New Study

A new study may confirm the risk of developing Fournier’s gangrene after taking diabetes drugs like Invokana. Fournier’s gangrene, a potentially life-threatening, flesh-eating genital infection, has allegedly caused the suffering of Invokana users according to lawsuits across the country.

JAMA Internal Medicine, a medical journal, recently published a research letter earlier this month that found an increased risk of Fournier’s gangrene among sodium-glucose contrasoperter-2 (SGLT-2) inhibitors. SGLT-2 inhibitors are a new class of diabetes drugs that help remove glucose from the body, including drugs like Invokana, Farxiga, and Jardiance. However, since Invokana, the first SGLT-2 inhibitor, was released to the market in 2013, researchers have been discovering numerous adverse health risks caused by Invokana and similar SGLT-2 inhibitors. In fact, the findings of this 2019 study confirm results first released by FDA researchers in 2018 that raised initial concerns about patients’ risk of developing Fournier’s gangrene from taking SGLT-2 inhibitors. JAMA analyzed the FDA’s 2018 findings of increased Fournier’s gangrene risk and published their evaluation in October 2018.

“Infections developed in all 12 patients within several months of starting an SGLT-2 inhibitor,” JAMA stated in their report. “All were hospitalized and required surgery that in some was disfiguring or resulted in complications. One patient died.”

JAMA indicated that there were likely far more cases of Fournier’s gangrene caused by Invokana and other SGLT-2 inhibitors than the FDA initially predicted.

However, though the risk of Fournier’s gangrene is present, the researchers of this most recent study indicate that the risk of infection does not outweigh the benefits of taking SGLT-2 inhibitors.

Invokana Lawsuits


After FDA researchers found an increased risk of patients developing Fournier’s gangrene after taking Invokana and similar drugs, the FDA ordered for new warning labels to be added to all SGLT-2 inhibitors, such as Invokana, Synjardy, Steglujan, etc. Previously, warning labels for serious side effects such as diabetic ketoacidosis, kidney failure, and amputation (specifically for Invokana) were added to SGLT-2 inhibitors’ packaging and information labels. When these drugs were first approved by the FDA, they did not carry warnings for any of these adverse side effects. As the first SGLT-2 inhibitor released to the market, Invokana manufacturers and sellers now face numerous lawsuits from injured Invokana users across the country. Invokana patients allege that Invokana manufacturers like Johnson & Johnson and Janssen were negligent in warning patients about the severe heath risks of taking Invokana, contributing to the injuries of patients across the country.

Recent Posts

Truvada Lawsuit Filed for Dangerous Side Effects of Tenofovir HIV Drugs

Allegations brought forward in a recent product liability lawsuit call out Gilead Sciences, Inc. for the dangerous side effects of their tenofovir-based HIV drugs, which include Truvada, Stribild, and Viread. Numerous lawsuits from across the U.S. allege tenofovir HIV drugs cause users to experience severe side effects, including kidney and bone injuries. Last week a […]

Read More
3M Earplug Bellwether Trial Scheduled for April 2021 Over Military Hearing Loss

The judge presiding over all federal 3M military earplug lawsuits announced that the first “bellwether” case in the litigation will go to trial April 5, 2021. This case, like the thousands of others in the litigation, allege 3M’s military earplugs were defective and caused veterans to suffer hearing severe injuries. Currently, over 150,000 earplug injury […]

Read More

Contact Us Today for your free, in-depth case evaluation

We're on Your Side
We're available 24/7
no fees unless you win

Free in-depth 
no obligation case evaluation

ATTORNEY ADVERTISEMENT: Not available in all states, Andrew Van Arsdale, supervising attorney is licensed only in California, Montana and Nevada, but associates with attorneys throughout the country, Principal office: 3667 Voltaire Street, San Diego, California 92106. 

Consult a doctor on all medical decisions. Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. No representation is made that the quality of the legal services performed is greater than the quality of the legal services performed by other lawyers. AVA Law Group, Inc. not accepting cases in states where this advertising conflicts with laws or state rules. Legal representation is not offered or available in Tennessee. While AVA Law Group, Inc. maintains joint responsibility, most cases are referred to other attorneys for principal responsibility.
envelopephone-handsetmap-markerarrow-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram